Pneumocystis carinii dihydropteroate synthase mutations and treatment with sulfa or sulfone regimens: a proposal for standardized definitions for clinical evaluation

J Eukaryot Microbiol. 2001:Suppl:180S-181S. doi: 10.1111/j.1550-7408.2001.tb00510.x.

Authors

L Huang¹, A M Morris, C B Beard

Affiliation

¹ Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, 94110, USA. lhuang@php.ucsf.edu

PMID: 11906054
DOI: 10.1111/j.1550-7408.2001.tb00510.x

No abstract available

MeSH terms

Anti-Infective Agents / therapeutic use*
Antibiotic Prophylaxis / standards
Dapsone / therapeutic use*
Dihydropteroate Synthase / genetics*
Humans
Mutation*
Pneumocystis / drug effects
Pneumocystis / enzymology
Pneumocystis / genetics
Pneumonia, Pneumocystis / drug therapy*
Pneumonia, Pneumocystis / microbiology
Pneumonia, Pneumocystis / mortality
Treatment Failure
Treatment Outcome
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use*

Substances

Anti-Infective Agents
Trimethoprim, Sulfamethoxazole Drug Combination
Dapsone
Dihydropteroate Synthase